Dupixent CTCL Litigation

Dupixent Litigation Updates

This page tracks selected litigation developments involving Dupixent, CTCL, and related T-cell lymphoma claims. Updates are intended to help patients and families understand major procedural developments, not to provide legal advice or guarantee any outcome. For medical and science background, visit Dupixent & CTCL.

Current status summary — June 2026

On June 4, 2026, the JPML granted centralization for federal Dupixent cases involving alleged CTCL and related claims. The litigation is now proceeding as MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey. Centralization coordinates related federal cases for pretrial proceedings; it does not decide causation, liability, or the merits of any individual claim.

Timeline (Newest First)

June 4, 2026

JPML Grants Dupixent MDL and Transfers Cases to New Jersey

What happened: The Judicial Panel on Multidistrict Litigation granted centralization for federal Dupixent cases involving alleged CTCL and related claims. The coordinated proceedings are now MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey.

Why it matters: Related federal cases will proceed together for coordinated pretrial work, including discovery, motions, expert issues, and other case-management steps. The order states that possible future expansion beyond CTCL cases can be addressed through the conditional transfer process.

The transfer order does not decide whether Dupixent caused CTCL or any related T-cell lymphoma, whether defendants are liable, or whether any individual claim will succeed. Individual review still depends on diagnosis, Dupixent use history, timing, medical records, state-law deadlines, and representation status.

For a fuller patient-facing explanation of what the new MDL means, read our resource: What the New Dupixent MDL Means for Patients Diagnosed With CTCL.

May 28, 2026

May 28, 2026 — JPML Hearing Scheduled

What is happening: The Judicial Panel on Multidistrict Litigation has scheduled oral arguments in MDL No. 3180, In re Dupixent (Dupilumab) Products Liability Litigation, for its May 28, 2026 hearing session in Milwaukee, Wisconsin.

What this means for patients: At a JPML hearing session, the Panel may consider whether related federal Dupixent CTCL cases should be transferred to one district court for coordinated pretrial proceedings.

The hearing does not decide causation, liability, or whether any individual claim should move forward. Patients considering review may want to preserve diagnosis, biopsy, dermatology, oncology, and prescription records.

Why it matters for people considering a case review: An MDL ruling is a litigation milestone, not a decision on the merits of any individual claim. People considering whether their Dupixent history warrants review do not need to wait for an MDL ruling to submit basic information.

April 16, 2026

April 16, 2026 — JPML Schedules Dupixent MDL Motion for May Hearing

What happened: The JPML filed a Notice of Hearing Session and Hearing Session Order scheduling MDL No. 3180, In re Dupixent (Dupilumab) Products Liability Litigation, for the May 28, 2026 hearing session in Milwaukee, Wisconsin.

Why it matters: A JPML hearing session is part of the process for considering whether related federal actions should be centralized for coordinated pretrial proceedings. Scheduling a hearing does not decide whether centralization will be granted and does not decide the merits of any individual claim.

February 13, 2026

February 13, 2026 — Plaintiffs Seek MDL Coordination for Dupixent T-Cell Lymphoma Cases

What happened: In filed JPML materials dated February 13, 2026, plaintiffs sought centralization of Dupixent T-cell lymphoma cases, identified fifteen actions, and proposed the Northern District of Georgia as the transferee court.

Why it matters: MDL coordination, if granted, can affect discovery, pretrial motions, expert issues, and case-management procedures. It does not decide whether any individual claim is valid.

Read Dupixent Lawsuit Overview

How to use these updates

Litigation updates can help patients and families understand where the Dupixent CTCL litigation stands procedurally. They may explain whether a JPML hearing has been scheduled, whether an MDL has been formed, or whether later court orders have changed the litigation timeline.

These updates are general litigation information. A person’s own review still depends on individual facts, including Dupixent use, diagnosis history, timing, and medical records.

If you want your own history reviewed, you may submit basic information through the initial review form.

Sources reviewed for this page

Motion for Transfer of Actions, Brief in Support, and Schedule of Actions, In re Dupixent Products Liability Litigation, MDL No. 3180, filed February 13, 2026.
Notice of Hearing Session and Hearing Session Order, In re Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, Document 40, filed April 16, 2026, scheduling the matter for the May 28, 2026 JPML hearing session.
JPML Transfer Order, In re: Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, filed June 4, 2026.

Last reviewed by Keke Feng, Esq. — June 9, 2026

Frequently Asked Questions

Is the Dupixent litigation already an MDL?

Yes. On June 4, 2026, the JPML granted centralization for federal Dupixent cases involving alleged CTCL and related claims. The coordinated proceedings are MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey.

What is the JPML?

The Judicial Panel on Multidistrict Litigation decides whether related federal cases should be transferred to one court for coordinated pretrial proceedings. The JPML does not make a final determination on causation, liability, or any individual claim.

What does MDL centralization mean?

MDL centralization brings related federal cases together in one district for coordinated pretrial proceedings, including discovery, motions, expert issues, and case management. It does not decide causation, liability, or the merits of any individual claim.

Why do MDL updates matter?

MDL developments may affect how related cases are organized for discovery, expert issues, pretrial motions, and case management. They can help patients and families understand the procedural stage of the litigation.

What should I watch for next?

Important future updates may include leadership appointments, early case-management orders, discovery schedules, expert proceedings, and conditional transfer activity involving related federal cases.

Can I request review while the litigation is still developing?

Yes. If you used Dupixent and were later diagnosed with CTCL or another related T-cell lymphoma, you may submit basic information for initial review while litigation developments continue.

Start Free Case Review

If you used Dupixent and were later diagnosed with CTCL or another related T-cell lymphoma, you may submit basic information for a focused initial review.

Start Free Case Review Call 888-271-9175